Atypical Carbapenem Antibiotics with Improved Activity Against Carbapenemase-Producing Acinetobacter baumannii
申请人:Buynak John
公开号:US20200339582A1
公开(公告)日:2020-10-29
The following invention deals with the design, preparation, evaluation, and use of carbapenem antibiotics with improved activity, relative to current commercially available carbapenem antibiotics, against infections involving multidrug resistant, carbapenemase-producing
Acinetobacter baumannii
. The new carbapenem antibiotics are demonstrated to possess not only inherent antimicrobial activity, but also the ability to inhibit OXA-23, the most commonly produced serine carbapenemase in this species. This unusual carbapenemase-inhibitory activity also indicates that the compounds may be used synergistically, in combination with current commercial carbapenem antibiotics, to inhibit key class D carbapenemases, such as OXA-23. Additionally, one of the newly reported carbapenems is active against metallo-beta-lactamase producing
A. baumannii
. This is the first report of a metallo-beta-lactamase stable carbapenem antibiotic. Structurally, the present invention describes carbapenem antibiotics which are modified in unusual ways, thus differentiating them from the common scaffold of all current commercial carbapenem antibiotics. In particular, these carbapenems have either an unusual C6 substituent, a hydroxymethyl group, replacing the common hydroxyethyl group, or they have an unusual C5 substituent, an alkyl group, replacing the common hydrogen atom at this position. Such atypical carbapenem antibiotics have not previously been investigated against resistant
A. baumannii
, nor have they been evaluated for stability to the class D carbapenemase, or the class B metallo-beta-lactamases.
以下发明涉及改进活性的碳青霉烯类抗生素的设计、制备、评估和使用,相对于当前市售的碳青霉烯类抗生素,用于对抗涉及多药耐药、碳青霉烯酶产生的鲍曼不动杆菌感染。新型碳青霉烯类抗生素不仅表现出固有的抗微生物活性,还具有抑制OXA-23的能力,这是该物种中最常见的丝氨酸碳青霉烯酶。这种不寻常的碳青霉烯酶抑制活性还表明,这些化合物可以与当前市售的碳青霉烯类抗生素协同使用,以抑制关键的D类碳青霉烯酶,如OXA-23。此外,新报道的碳青霉烯类抗生素之一对产生金属β-内酰胺酶的鲍曼不动杆菌具有活性。这是金属β-内酰胺酶稳定碳青霉烯类抗生素的首次报告。在结构上,本发明描述了以不寻常方式改良的碳青霉烯类抗生素,从而使它们与所有当前市售的碳青霉烯类抗生素的共同支架有所区别。特别是,这些碳青霉烯类抗生素具有不寻常的C6取代基,一个羟甲基基团,取代了常见的羟乙基基团,或者它们具有不寻常的C5取代基,一个烷基基团,取代了此位置的常见氢原子。此类非典型碳青霉烯类抗生素以前尚未针对耐药鲍曼不动杆菌进行过研究,也未对其稳定性进行过类D碳青霉烯酶或类B金属β-内酰胺酶的评估。